Eli Lilly Due Diligence Report

Major pharma with blockbuster GLP-1 drugs (Mounjaro, Zepbound) for diabetes and obesity. $45B+ revenue, largest healthcare market cap globally.

What Our Eli Lilly Diligence Report Covers

• Business Overview — Revenue model, key products/services, market position, and growth trajectory
• Financial Snapshot — Revenue, profitability margins, balance sheet health, and cash position
• Risk Flags — Regulatory exposure, litigation, customer concentration, and supply chain dependencies
• Competitive Landscape — Key competitors, market share dynamics, and competitive moats
• Management Assessment — Leadership track record, insider ownership, and governance quality
• Recent Developments — Latest news, product launches, M&A activity, and strategic shifts
• Diligence Score — Overall quantitative score (0-100) with component breakdowns

Full Report Also Includes

• Detailed 3-year financial analysis with trend projections
• Comparable transactions and precedent deal multiples
• Risk register with probability and impact ratings
• Regulatory and compliance deep-dive
• Investment committee workplan template